antileishmanial agents (DNDi/Pfizer/WuXi PharmaTech/iThemba)

N/A

Report date: 2025/03/14 20:00:48
NME

Base Information

Drug Nameantileishmanial agents (DNDi/Pfizer/WuXi PharmaTech/iThemba)
Drug Alias NameN/A
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionUpdating
TargetsUpdating
Therapy Area/IndicationsLeishmania donovani infection
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritorySouth AfricaSwitzerlandUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaPending
Originator CompaniesDrugs For Neglected Diseases Initiative
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesiThemba Pharmaceuticals Pty LtdPfizer IncDrugs For Neglected Diseases Initiative +[4] 
Active IndicationsN/A
Inactive IndicationsLeishmania donovani infection

Other Information

ATC CodeN/A
Related LinksN/A